Nanomedicine
Group Leader: Kostas Kostarelos
Main Research Lines
-
Nanomaterials as vector systems for therapeutic and diagnostic applications
-
Development of graphene and 2D materials in medicine
-
Clinical translation of bioelectronic devices
-
Discovery of novel biomarkers and therapeutic targets in oncology and neurology
The Nanomedicine@ICN2 group, established at the end of 2019, is dedicated to the development of nanomaterials and devices for therapeutic and diagnostics applications. It has strong links with the Nanomedicine Lab at the Faculty of Biology, Medicine and Health at the University of Manchester, with Prof. Kostas Kostarelos leading both teams. Graphene and 2D materials have a central role in a number of research lines carried out by the group in the context of the Graphene Flagship and beyond. The group also works on liposomes and other nanoparticle systems for various biomedical applications, ranging from cancer therapeutics to neurodegenerative disease interventions.
Group Leader
Kostas Kostarelos
Severo Ochoa Distinguished Professor and Group Leader
kostas.kostarelos@icn2.cat
Prof. Kostas Kostarelos read Chemistry at the University of Leeds and obtained his Diploma in Chemical Engineering and his PhD from the Department of Chemical Engineering at Imperial College London, studying the steric stabilization of liposomes using block copolymer molecules.
He carried out his postdoctoral training in various medical institutions in the USA (UCSF, Memorial Sloan-Kettering Cancer Center, Cornell). Following his promotion to Assistant Professor of Genetic Medicine and Chemical Engineering in Medicine at Cornell University Weill Medical College, he relocated to the UK as the Deputy Director of Imperial College Genetic Therapies Centre in 2002. In 2007 Kostarelos was awarded the first personal Chair of Nanomedicine in the UK and was Head of the Centre for Drug Delivery at the UCL School of Pharmacy in London.